† Study has passed its completion date and status has not been verified in more than two years.
Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease
A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function
|3||Active, not recruiting||
Safety and Efficacy of LCI699 in Cushing's Disease Patients.
A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function
An Evaluation of the Effects of LCI699 on Cortisol in Patients With Hypertension
Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism
A Study to Evaluate the Effects of LCI699 on Safety and Efficacy in Subjects With Resistant Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic
A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Dose Finding Study to Evaluate the Efficacy and Safety of LCI699, a New Experimental Antihypertensive Drug, in Patients With Essential Hypertension
Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome
Efficacy and Safety Evaluation of Osilodrostat in Cushing's Disease